Ascendis Pharma A/S (ASND) Rating Increased to Strong-Buy at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a strong-buy rating in a research report report published on Wednesday.

A number of other equities research analysts also recently weighed in on ASND. Canaccord Genuity began coverage on Ascendis Pharma A/S in a research report on Tuesday, August 7th. They set a buy rating and a $81.00 target price on the stock. Zacks Investment Research raised Ascendis Pharma A/S from a hold rating to a strong-buy rating and set a $72.00 target price on the stock in a research report on Tuesday, October 30th. BidaskClub downgraded Ascendis Pharma A/S from a buy rating to a hold rating in a research report on Friday, September 7th. Stifel Nicolaus decreased their target price on Ascendis Pharma A/S from $85.00 to $81.00 and set a buy rating on the stock in a research report on Thursday, August 30th. Finally, JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $79.00 to $81.00 and gave the stock an overweight rating in a research report on Thursday, August 30th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $77.56.

ASND stock opened at $64.71 on Wednesday. Ascendis Pharma A/S has a twelve month low of $36.07 and a twelve month high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.29. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.16 million. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.01 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. PNC Financial Services Group Inc. acquired a new stake in Ascendis Pharma A/S during the second quarter valued at approximately $350,000. Quantitative Systematic Strategies LLC acquired a new stake in Ascendis Pharma A/S during the second quarter valued at approximately $361,000. Meadow Creek Investment Management LLC boosted its holdings in Ascendis Pharma A/S by 12.1% during the second quarter. Meadow Creek Investment Management LLC now owns 6,952 shares of the biotechnology company’s stock valued at $462,000 after purchasing an additional 748 shares in the last quarter. Glen Harbor Capital Management LLC boosted its holdings in Ascendis Pharma A/S by 12.1% during the second quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 952 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Ascendis Pharma A/S by 153.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 5,107 shares in the last quarter. 95.60% of the stock is currently owned by institutional investors.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: Diversification

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.